We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+10.28%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.07B
AUM Growth
-$11.6M
(-0.23%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-2.83%
Top 10 Holdings %
Top 10 Hldgs %
24.83%
Holding
159
New
22
Increased
53
Reduced
27
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Evolent Health
EVH
|
+$48.3M |
| 2 |
Flywire
FLYW
|
+$47.9M |
| 3 |
dLocal
DLO
|
+$36.1M |
| 4 |
DoubleVerify
DV
|
+$35.7M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$31.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cintas
CTAS
|
+$108M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$106M |
| 3 |
Biohaven
BHVN
|
+$74.9M |
| 4 |
KNBE
KnowBe4, Inc. Class A Common Stock
KNBE
|
+$68M |
| 5 |
MongoDB
MDB
|
+$57.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.02% |
| 2 | Technology | 23.53% |
| 3 | Industrials | 12.87% |
| 4 | Consumer Discretionary | 5.44% |
| 5 | Utilities | 4.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Compass Therapeutics
CMPX
$349M
| $4.7M | 0.09% |
935,091
-165,308
| -15% | -$659K |
|
127
Ionis Pharmaceuticals
IONS
$8.85B
| $4.15M | 0.08% |
110,000
| – | – |
|
128
XPO
XPO
$23.4B
| $3.83M | 0.08% |
115,000
-78,545
| -41% | -$2.65M |
|
|
NEE.PRR
129
DELISTED
NextEra Energy, Inc. 6.926% Corporate Units
NEE.PRR
| $3.76M | 0.07% |
+75,000
| New | +$3.6M |
|
|
FRLN
130
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $2.92M | 0.06% |
394,718
-1,949
| -0.5% | -$18.6K |
|
131
Arteris
AIP
$1.35B
| $2.64M | 0.05% |
614,173
+218,152
| +55% | +$1.1M |
|
132
Zoetis
ZTS
$31.9B
| $1.99M | 0.04% |
13,564
-17,183
| -56% | -$2.54M |
|
133
RXO
RXO
$3.39B
| $1.98M | 0.04% |
+115,000
| New | +$2.04M |
|
|
KALV
134
DELISTED
KalVista Pharmaceuticals
KALV
| $1.87M | 0.04% |
276,200
| – | – |
|
|
TRML
135
DELISTED
Tourmaline Bio
TRML
| $1.59M | 0.03% |
156,109
| – | – |
|
136
Workday
WDAY
$39B
| $309K | 0.01% |
+1,847
| New | +$288K |
|
137
Edwards Lifesciences
EW
$50B
| $195K | ﹤0.01% |
+2,607
| New | +$201K |
|
138
ServiceNow
NOW
$114B
| $185K | ﹤0.01% |
+2,380
| New | +$186K |
|
139
NextEra Energy
NEE
$183B
| $185K | ﹤0.01% |
+2,207
| New | +$178K |
|
140
O'Reilly Automotive
ORLY
$71.3B
| $159K | ﹤0.01% |
+2,820
| New | +$152K |
|
141
TSMC
TSM
$2.09T
| $115K | ﹤0.01% |
1,544
-410,283
| -100% | -$29.7M |
|
142
NVIDIA
NVDA
$4.72T
| $82.1K | ﹤0.01% |
+5,620
| New | +$82.4K |
|
143
NXP Semiconductors
NXPI
$61.8B
| $58.3K | ﹤0.01% |
+369
| New | +$58.5K |
|
144
Agilent Technologies
A
$39.2B
| – | – |
-358,200
| Closed | -$43.5M |
|
145
Arvinas
ARVN
$536M
| – | – |
-281,500
| Closed | -$12.5M |
|
146
BioAtla
BCAB
$5.61M
| – | – |
-15,900
| Closed | -$6.12M |
|
|
147
Biohaven
BHVN
$2.08B
| – | – |
-506,827
| Closed | -$74.9M |
|
|
148
Cintas
CTAS
$82.8B
| – | – |
-1,109,684
| Closed | -$108M |
|
|
EPIX
149
DELISTED
ESSA Pharma
EPIX
| – | – |
-1,561,251
| Closed | -$2.84M |
|
150
Generac Holdings
GNRC
$11.3B
| – | – |
-269,700
| Closed | -$48M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Eventide Asset Management held 159 positions worth $5.07B, down 0.23% from $5.08B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Eventide Asset Management's Q4 2022 filing shows 22 new, 53 increased, 27 reduced and 17 closed positions. Its largest new stake was Seagen Inc. Common Stock: 242,545 shares worth $31.2M. The largest sale was Cintas, an estimated $108M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 39% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q4 2022 buy was Seagen Inc. Common Stock: 242,545 shares worth $31.2M.
- Eventide Asset Management added most to Evolent Health in Q4 2022, an estimated $48.3M increase.
- Eventide Asset Management's biggest Q4 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $106M.
- Eventide Asset Management fully exited Cintas in Q4 2022, selling an estimated $108M.
- Eventide Asset Management's ten largest holdings make up 25% of its $5.07B portfolio in Q4 2022.
- Eventide Asset Management opened 22 new positions and closed 17 in Q4 2022.
- Eventide Asset Management's portfolio value fell 0.23% quarter-over-quarter to $5.07B.
Based on Eventide Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.